サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629876

インライン血液モニタリング装置の世界市場-2025～2033年

Global In-Line Blood Monitoring Devices Market - 2025-2033

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
インライン血液モニタリング装置の世界市場-2025～2033年
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

インライン血液モニタリング装置の世界市場は、2024年に1億63万410米ドルに達し、2033年には3億1,789万1,080米ドルに達すると予測され、予測期間2025～2033年のCAGRは11.6%で成長します。

インライン血液モニタリング装置は、患者の血液のさまざまな重要パラメータをリアルタイムで継続的に測定・評価するために使用される医療機器であり、一般的には外科手術、集中治療、または心肺バイパス、透析、ECMO（体外膜酸素化）などの体外治療の際に使用されます。これらの装置は血液循環経路に直接組み込まれるため、繰り返し血液を採取する必要がなく、非侵襲的または低侵襲的なモニタリングが可能です。

インライン血液モニタリング装置の需要が大きく伸びているのは、体外循環を必要とする外科手術の増加や、移植などの重要な心臓血管手術の増加といった要因によるものです。例えば、Mass General Brigham Organizationによると、冠動脈バイパス手術を含む90万件以上の心臓手術が毎年米国で行われており、世界中でさらに多くの手術が行われています。心臓手術は心臓と、肺動脈や大動脈などの太い血管に対して行われます。

また、ScienceDirectによると、外科手術は最近、国の医療制度に不可欠なものとして認識されていますが、約50億人が、必要なときに安全で安価な外科治療をタイムリーに受けられないままとなっています。毎年1,700万人以上が外科的に予防可能な疾患で死亡しており、毎年行われる3億1,300万件の外科手術のうち、最も貧しい3分の1の人口に対して行われる手術はわずか6%です。この地域では外科的ケアの必要性が最も高いです。こうした外科手術の増加は、インライン血液モニタリング装置市場の需要を増大させています。

市場力学：

促進要因と抑制要因

心血管疾患および重篤な疾患の有病率の増加

心血管系疾患や敗血症、脳卒中、呼吸不全などの重篤な疾患の増加は、インライン血液モニタリング装置市場の成長を大きく促進しています。これらの疾患では、酸素濃度、血液ガス、電解質、ヘモグロビンなどの重要な血液パラメータを常にリアルタイムでモニタリングする必要があります。インライン血液モニタリング装置は、集中治療室（ICU）、手術室、救急医療環境において、患者ケアを最適化するために、継続的で非侵襲的かつ正確な評価を提供する上で非常に重要です。

例えば、世界保健機関（WHO）によると、心血管疾患（CVD）は世界の死因の第一位であり、毎年1,790万人の命が奪われていると推定されています。この心血管疾患による死亡者数の増加により、冠動脈バイパス術、心臓移植、その他の心臓血管手術のようなリスクの高い手術中の高度なモニタリングの需要が高まっています。

インライン血液モニタリング装置は、特に心臓手術において、血中酸素飽和度、pHレベル、二酸化炭素濃度などのパラメーターをリアルタイムで追跡することを可能にし、これらの複雑な手術中の患者の安定管理に不可欠です。

高血圧やその他の心血管系疾患の危険因子の世界の増加は、治療中や術後の回復中の合併症を防ぐために血液パラメーターを継続的にモニターする必要性が高まっていることと直結しています。

例えば、世界保健機関（WHO）によると、世界で30～79歳の成人12億8,000万人が高血圧であると推定され、そのほとんど（3分の2）は低・中所得国に住んでいます。高血圧の成人の推定46％は、自分が高血圧であることに気づいていません。高血圧と診断され治療を受けているのは、成人の半数以下（42％）です。高血圧をコントロールできているのは、成人の約5人に1人（21％）です。

既存システムとの統合の複雑さ

既存のヘルスケアシステムとの統合の複雑さは、世界のインライン血液モニタリング装置市場の成長を妨げる重要な課題です。これらの機器は継続的なリアルタイムモニタリングのための高度な機能を提供しますが、病院情報システム（HIS）や電子カルテ（EHR）、その他の臨床インフラとの統合は依然として大きなハードルとなっています。

多くのヘルスケア施設は、最新のモニタリング機器とシームレスにインターフェースできるように設計されていないレガシーシステムに依存しています。古いEHRシステムや病院管理ソフトウェアは、新しいインラインモニタリング技術との互換性に欠けていることが多いです。

Healthcare IT Newsの調査によると、医療提供者の80%は、新しい診断技術を既存のインフラに統合する際に問題に直面しています。インライン血液モニタリング装置は、データトランスミッションと分析のために既存のプラットフォームと統合する必要がありますが、これら旧式のシステムは、遅延、エラー、あるいはデータの損失を引き起こす可能性があります。

連続血液モニタリング装置を病院のITシステムと統合することは、データセキュリティとプライバシーの重大な問題を引き起こします。例えば、HIPAAジャーナルによると、2023年8月には2,300万件のヘルスケア記録の漏洩が指摘されています。過去12ヶ月間、毎月平均9,989,003件のヘルスケア記録が漏洩しています。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • モダリティ別スニペット
  • 製品別スニペット
  • 用途別スニペット
  • 地域別スニペット

第3章 市場力学

  • 影響要因
    • 促進要因
      • 心血管疾患および重篤疾患の罹患率の増加
      • 体外循環を必要とする外科手術の増加
    • 抑制要因
      • 既存システムとの統合の複雑さ
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 インライン血液モニタリング装置市場、モダリティ別

  • ベンチトップ
  • ポータブル

第6章 インライン血液モニタリング装置市場、製品別

  • インライン血液モニタリング装置
  • 消耗品

第7章 インライン血液モニタリング装置市場、用途別

  • 心肺バイパス手術
  • 移植手術
  • 先天性心疾患の手術
  • ECMO
  • その他

第8章 インライン血液モニタリング装置市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場プレーヤー
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Terumo Corporation
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • LivaNova PLC
  • Eurosets S.r.l.
  • Spectrum Medical Ltd.

第11章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第12章 付録

目次
Product Code: MD8906

The global In-line blood monitoring devices market reached US$ 100,630.41 thousand in 2024 and is expected to reach US$ 317,891.08 thousand by 2033, growing at a CAGR of 11.6% during the forecast period 2025-2033.

In-line blood monitoring devices are medical instruments used to continuously measure and assess various critical parameters of a patient's blood in real-time, typically during surgical procedures, intensive care or extracorporeal treatments such as cardiopulmonary bypass, dialysis, or ECMO (Extracorporeal Membrane Oxygenation). These devices are integrated directly into the blood circulation pathway, allowing for non-invasive or minimally invasive monitoring without requiring repeated blood sampling.

The demand for In-line blood monitoring devices is experiencing significant growth, which is attributed to factors such as growing surgical procedures requiring extracorporeal circulation and the growing critical cardiovascular procedures such as transplantations. For instance, according to the Mass General Brigham Organization, more than 900,000 cardiac surgeries, including coronary bypass surgeries, are performed in the U.S. every year, with even more taking place throughout the world. Cardiac surgery is performed on the heart and its large blood vessels, including the pulmonary arteries and the aorta.

Additionally, according to ScienceDirect, surgery has recently been recognized as an integral part of national health systems, yet approximately 5 billion people remain without timely access to safe and affordable surgical care when needed. More than 17 million people die of surgically preventable conditions every year, and only 6% of the 313 million surgical interventions taking place every year occur in the poorest one-third of the world's population, in whom the need for surgical care is highest. These rising surgical procedures increase the demand for in-line blood monitoring devices market.

Market Dynamics: Drivers & Restraints

Increasing prevalence of cardiovascular and critical conditions

The increasing prevalence of cardiovascular diseases and critical conditions like sepsis, stroke and respiratory failure is significantly driving the growth of the In-line blood monitoring devices market. These conditions require constant, real-time monitoring of critical blood parameters, such as oxygen levels, blood gases, electrolytes and hemoglobin. In-line blood monitoring devices are critical in providing continuous, non-invasive and accurate assessments to optimize patient care in intensive care units (ICUs), operating rooms and emergency care settings.

For instance, according to the World Health Organization (WHO), Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This rising cardiovascular deaths has spurred the demand for advanced monitoring during high-risk procedures like coronary artery bypass, heart transplants and other cardiovascular surgeries.

In-line blood monitoring devices, particularly in cardiac surgeries, enable real-time tracking of parameters such as blood oxygen saturation, pH levels and carbon dioxide concentrations, essential for managing patient stability during these complex procedures.

The global rise in hypertension and other risk factors for cardiovascular diseases directly correlates to an increasing need for continuous monitoring of blood parameters to prevent complications during treatments or post-surgical recovery.

For instance, according to the World Health Organization, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. An estimated 46% of adults with hypertension are unaware that they have the condition. Less than half of adults (42%) with hypertension are diagnosed and treated. Approximately 1 in 5 adults (21%) with hypertension have it under control.

Complexity of integration with existing systems

The complexity of integration with existing healthcare systems is a key challenge hampering the growth of the global In-line blood monitoring devices market. While these devices offer advanced capabilities for continuous, real-time monitoring, integrating them with hospital information systems (HIS), electronic health records (EHR) and other clinical infrastructure remains a significant hurdle.

Many healthcare facilities still rely on legacy systems that were not designed to interface seamlessly with modern monitoring devices. Older EHR systems or hospital management software often lack compatibility with newer in-line monitoring technologies.

A study by Healthcare IT News highlighted that 80% of healthcare providers still face issues integrating newer diagnostic technologies into their existing infrastructure. In-line blood monitoring devices need to be integrated with existing platforms for data transmission and analysis, but these outdated systems can cause delays, errors or even data loss.

Integrating continuous blood monitoring devices with hospital IT systems raises significant data security and privacy issues. For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records were noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month.

Segment Analysis

The global In-line blood monitoring devices market is segmented based on modality, product, application and region.

Product:

The In-line blood monitoring devices segment is expected to dominate the market

The In-line blood monitoring devices segment is expected to dominate the global market. The In-line blood monitoring devices are crucial for diagnosing various medical conditions, including respiratory failure, metabolic disorders and conditions affecting oxygenation. Healthcare providers often utilize this during surgeries by integrating with heart-lung machines to make timely decisions regarding patient care. By assessing parameters such as partial pressures of oxygen (PaO2), carbon dioxide (PaCO2) and bicarbonate levels, clinicians can determine the adequacy of ventilation and oxygenation, guiding interventions like oxygen therapy or mechanical ventilation.

The companies are developing advanced in-line blood monitoring devices that meet the safety and regulatory standards that are set by the regulatory bodies. For instance, in March 2024, Terumo Cardiovascular received the FDA 510(k) clearance for its next-generation CDI OneView monitoring system. Terumo's CDI systems display patient parameters during cardiopulmonary bypass surgery to support perfusion safety and improve patient outcomes. This new CDI OneView system measures or displays up to 22 vital patient parameters, including oxygen delivery, cardiac index, area under the indexed oxygen delivery curve, oxygen extraction ratio and measured flow.

Additionally in August 2024, LivaNova received the FDA 510(k) clearance and CE mark for its Essenz in-line blood monitor. Essenz ILBM provides accurate and continuous measurement of essential blood parameters throughout cardiopulmonary bypass (CPB) procedures, according to LivaNova. It integrates into the next-generation Essenz perfusion system. Essenz enables perfusionists to access and manage reliable blood parameters directly from the system's cockpit. It eliminates the need for additional monitors or holders.

Geographical Analysis

North America is expected to hold a significant position in the In-line blood monitoring devices market share

North America is expected to hold the largest market share in the global In-line blood monitoring devices market. The increasing prevalence of chronic diseases and the rising number of cardiac surgeries driving the in-line blood monitoring devices market. The use of in-line monitoring devices in operating rooms for cardiac bypass surgeries is a crucial factor in the healthcare landscape of North America. With a substantial number of Coronary Artery Bypass Grafting (CABG) procedures performed annually, the demand for advanced monitoring technologies is essential for ensuring patient safety and enhancing surgical outcomes.

For instance, as per ScienceDirect research in June 2024, the average total cardiac surgical volume across 24 countries with available data was 123.2 surgeries per 100,000 population per year. This figure varies significantly by country, with South Korea reporting a low of 27.3 surgeries per 100,000 and the United States exhibiting the highest rate at 271.5 surgeries per 100,000. This increasing surgery number demands in-line blood monitoring devices in the U.S. market.

The increasing prevalence of cardiovascular diseases is driving the need for advanced monitoring devices during surgical interventions. As a greater number of patients undergo surgeries that involve cardiopulmonary bypass, there is a demand for dependable in-line blood monitoring devices.

For instance, according to the Centers for Disease Control and Prevention (CDC), cardiovascular disease remains the leading cause of death for both men and women across various racial and ethnic groups in the United States. In 2022, around 702,880 individuals lost their lives to heart disease, which translates to approximately 1 in every 5 deaths. With a person succumbing to cardiovascular disease every 33 seconds, there is an urgent need for prompt and precise medical interventions in clinical environments. The implementation of continuous blood monitoring can significantly enhance patient outcomes during critical surgical procedures.

Asia-Pacific is growing at the fastest pace in the In-line blood monitoring devices market

The Asia-Pacific region is experiencing the fastest growth in the In-line blood monitoring devices market. The increasing number of bypass surgeries and heart-lung transplants in the Asia-Pacific region is a significant driving factor for the in-line monitoring devices market indicating an increasing demand for surgical interventions aimed at treating severe cardiovascular diseases. As more patients undergo these procedures, there is a corresponding need for effective in-line monitoring devices that can continuously track vital signs, including heart rate, blood pressure, oxygen saturation, and other critical parameters during surgery.

The increase in Coronary Artery Bypass Grafting (CABG) procedures in India signifies a growing demand for effective cardiac interventions. As more patients undergo CABG, the need for reliable in-line blood monitoring devices becomes crucial to ensure patient safety and optimize surgical outcomes. Continuous monitoring of vital parameters such as blood pressure, heart rate, and oxygen saturation is essential during these complex surgeries.

For instance, according to the Times of India (TOI), the increase in bypass surgeries among patients in their early to mid-30s by 30% over the past decade, with an annual rise of 5%, is a significant driving factor for the in-line blood monitoring devices market. This trend reflects a concerning shift in cardiovascular health, indicating that heart attacks and related diseases are becoming more prevalent in younger individuals.

Additionally, according to the Journal of the Practice of Cardiovascular Sciences, in India, 1,328 heart transplants, 475 lung transplants, 128 Left Ventricular Assist Device (LVAD) implants, and 61 lung transplants for COVID-19 lung disease completed by March 2023, highlights significant advancements in the field of organ transplantation. The annual figures show a steady number of procedures, with 129 lung transplants performed in 2023 and 62 in 2024 up to July, alongside 102 heart transplants in 2023 and 62 in 2024 until July. This upward trend in complex surgical procedures is a crucial driver for the inline monitoring devices market in the region.

Competitive Landscape

The major global players in the In-line blood monitoring devices market include Terumo Corporation, LivaNova PLC, Eurosets S.r.l. and Spectrum Medical Ltd.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global In-line blood monitoring devices market report delivers a detailed analysis with 44 key tables, more than 48 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Modality
  • 2.4. Snippet by Product
  • 2.5. Snippet by Application
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Prevalence of Cardiovascular and Critical Conditions
      • 3.1.1.2. Growing Surgical Procedures Requiring Extracorporeal Circulation
    • 3.1.2. Restraints
      • 3.1.2.1. Complexity of Integration with Existing Systems
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. In-Line Blood Monitoring Devices Market, By Modality

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 5.1.2. Market Attractiveness Index, By Modality
  • 5.2. Bench Top*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Portable

6. In-Line Blood Monitoring Devices Market, By Product

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. In-Line Blood Monitoring Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Consumables

7. In-Line Blood Monitoring Devices Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cardiopulmonary Bypass Procedures*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Transplant Procedures
  • 7.4. Congenital Heart Procedures
  • 7.5. ECMO
  • 7.6. Others

8. In-Line Blood Monitoring Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Terumo Corporation*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. LivaNova PLC
  • 10.3. Eurosets S.r.l.
  • 10.4. Spectrum Medical Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us